Ingrid Gause-Nilsson
Overview
Explore the profile of Ingrid Gause-Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zelniker T, Wiviott S, Mosenzon O, Goodrich E, Jarolim P, Cahn A, et al.
JAMA Cardiol
. 2023 Mar;
8(5):503-509.
PMID: 36857035
Importance: Dapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on...
2.
Furtado R, Raz I, Goodrich E, Murphy S, Bhatt D, Leiter L, et al.
Circulation
. 2022 May;
145(21):1581-1591.
PMID: 35510542
Background: Dapagliflozin improved heart failure and kidney outcomes in patients with type 2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the DECLARE-TIMI 58 trial (Dapagliflozin...
3.
Kolkailah A, Wiviott S, Raz I, Murphy S, Mosenzon O, Bhatt D, et al.
Diabetes Care
. 2022 Jan;
45(2):e27-e29.
PMID: 35020832
No abstract available.
4.
Zelniker T, Raz I, Mosenzon O, Dwyer J, Heerspink H, Cahn A, et al.
JAMA Cardiol
. 2021 Apr;
6(7):801-810.
PMID: 33851953
Importance: Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The...
5.
ODonoghue M, Kato E, Mosenzon O, Murphy S, Cahn A, Herrera M, et al.
Diabetologia
. 2021 Feb;
64(6):1226-1234.
PMID: 33611623
Aims/hypothesis: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces...
6.
Zelniker T, Morrow D, Mosenzon O, Goodrich E, Jarolim P, Murphy S, et al.
Eur J Heart Fail
. 2020 Dec;
23(6):1026-1036.
PMID: 33269486
Aims: Dapagliflozin reduced the risk of the composite of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus in DECLARE-TIMI 58. We hypothesized...
7.
Zelniker T, Bonaca M, Furtado R, Mosenzon O, Kuder J, Murphy S, et al.
Circulation
. 2020 Jan;
141(15):1227-1234.
PMID: 31983236
Background: Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes mellitus and its related comorbidities, including hypertension, obesity, and heart failure (HF). SGLT2 (sodium-glucose cotransporter 2) inhibitors...
8.
Kato E, Silverman M, Mosenzon O, Zelniker T, Cahn A, Furtado R, et al.
Circulation
. 2019 Mar;
139(22):2528-2536.
PMID: 30882238
Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure...
9.
Kosiborod M, Gause-Nilsson I, Xu J, Sonesson C, Johnsson E
J Diabetes Complications
. 2017 Mar;
31(7):1215-1221.
PMID: 28284707
Aim: We investigated the efficacy and safety of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). Methods: Data for patients...
10.
Sonesson C, Johansson P, Johnsson E, Gause-Nilsson I
Cardiovasc Diabetol
. 2016 Feb;
15:37.
PMID: 26895767
Background: A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV...